See veebileht kasutab küpsiseid kasutaja sessiooni andmete hoidmiseks. Veebilehe kasutamisega nõustute ETISe kasutustingimustega. Loe rohkem
Olen nõus
"Muu" projekt MP1GV07236R
MP1GV07236R "European Network for Genetic and Genomic Epidemiology (1.01.2008−31.12.2012)", Andres Metspalu, Tartu Ülikool, Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu.
MP1GV07236R
European Network for Genetic and Genomic Epidemiology
1.01.2008
31.12.2012
Teadus- ja arendusprojekt
Muu
ValdkondAlamvaldkondCERCS erialaFrascati Manual’i erialaProtsent
3. Terviseuuringud3.11. Terviseuuringutega seotud uuringud, näiteks biokeemia, geneetika, mikrobioloogia, biotehnoloogia, molekulaarbioloogia, rakubioloogia, biofüüsika ja bioinformaatikaB790 Kliiniline geneetika3.1. Biomeditsiin (anatoomia, tsütoloogia, füsioloogia, geneetika, farmaatsia, farmakoloogia, kliiniline keemia, kliiniline mikrobioloogia, patoloogia)100,0
AsutusRollPeriood
Tartu Ülikoolpartner01.01.2008−31.12.2012
Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramupartner01.01.2008−31.12.2012
AsutusRiikTüüp
Euroopa Komisjon
PerioodSumma
01.01.2008−31.12.20122 487 810,00 EEK (159 000,04 EUR)
159 000,04 EUR
7. raamprogramm

European Network for Genetic and Genomic Epidemiology. The primary aim of project is to translate the wealth of data emerging from large-scale research efforts in genetic and genomic epidemiology conducted in well-characterized European (and other) samples into information of relevance to future clinical advances. The practical impacts of the project societal WP 8 include policy guidance for project members, the development of templates for consent, confidentiality and commercialization templates specific to metabolic syndrome-CVD, and codes of conduct for clinicians. Technology platforms themselves will be a crucial commercial deliverable from this collaborative project. In addition to technology platforms, biomarkers as predictors of disease onset or progression would establish a potentially valuable intellectual property position for commercial exploitation.Knowledge of genetic susceptibility and understanding the relationship between genetic and life-tyle/environmental risk factors will be of great importance in national and international public health strategies. Finally education of public and proper analyses of the societal impact of this new information will be critical for the implementation of this data to the improvement of our welfare. Also this element is studies and potential new delivery tools produced by project.
European Network for Genetic and Genomic Epidemiology. The primary aim of project is to translate the wealth of data emerging from large-scale research efforts in genetic and genomic epidemiology conducted in well-characterized European (and other) samples into information of relevance to future clinical advances. The practical impacts of the project societal WP 8 include policy guidance for project members, the development of templates for consent, confidentiality and commercialization templates specific to metabolic syndrome-CVD, and codes of conduct for clinicians. Technology platforms themselves will be a crucial commercial deliverable from this collaborative project. In addition to technology platforms, biomarkers as predictors of disease onset or progression would establish a potentially valuable intellectual property position for commercial exploitation.Knowledge of genetic susceptibility and understanding the relationship between genetic and life-tyle/environmental risk factors will be of great importance in national and international public health strategies. Finally education of public and proper analyses of the societal impact of this new information will be critical for the implementation of this data to the improvement of our welfare. Also this element is studies and potential new delivery tools produced by project.